Device designed to help clinicians detect lesions in the colon during a colonoscopy
News
C4X Discovery agrees licensing deal with Sanofi
Sanofi could pay up to €414m for C4X Discovery’s oral IL-17A inhibitor programme
Early promise for new immunotherapy combo in brain cancer
Experimental drug plus immunotherapy demonstrated early potential in aggressive brain cancer
Farxiga fails to achieve statistical significance in COVID-19 trial
Diabetes drug was unable to prevent all-cause mortality in Phase III study
EU nod for new formulation of Biogen’s Tysabri
A subcutaneous formulation will now be available to treat relapsing-remitting multiple sclerosis
NICE ‘no’ for Opdivo/Yervoy lung cancer combo
The combination is not considered to be a cost-effective use of NHS resources in this setting
Human trials for world’s first AI-designed immuno-oncology drug
The drug was discovered through an AI-design platform within just eight months of project initiation
Lilly, Incyte’s Olumiant fails in COVID-19 trial
The drug failed to significantly reduce progression to ventilation or death in patients hospitalised with COVID-19
Achilles’ US IPO closed with proceeds of $175m
The Cancer Research UK spinout is developing precision T cell therapies to treat multiple cancers
Novartis bags EU, UK licences for MS therapy Kesimpta
Kesimpta is the first self-administered B-cell therapy for patients with relapsing forms of multiple sclerosis
Benefits of AZ vaccine outweigh risks, says MHRA
The risk of rare blood clots is currently calculated at four people in a million who receive the vaccine
Coronavirus infections drop but R number remains at 1
Data suggest infections in England fell by 60% from February, but the decline is levelling
Novartis UK announces further HRT patch stock issues
Supplies of Estradot TTS-75 are expected to return to normal within eight weeks
Nationwide launch for pioneering fertility study
The NIHR-funded trial will assess whether removing small fibroids and endometrial polyps improves fertility and live births
Artios, Novartis form cancer therapies collaboration
The deal could be worth as much as $1.3 billion to Artios
